April 11, 2021

Novartis Egypt launches campaign to address critical risk of high blood cholesterol

46% of deaths in country caused by cardiovascular disease

The Egypt operations of global pharmaceutical company, Novartis, launched on Thursday an awareness campaign highlighting the dangers of living with elevated blood cholesterol levels, hypercholesterolemia.

The campaign raises awareness of the risks and complications of high blood cholesterol levels, especially low-density lipoprotein cholesterol (LDL-C) known as ‘bad’ cholesterol, and encourages testing and greater treatment adherence.

Annually, cardiovascular disease (CVD) kills more than 18 million globally, a figure that is expected to reach over 24 million by 2030. There is a well-established link between atherosclerotic cardiovascular disease (ACVD) and elevated LDL-C levels.

Gehan Ramadan, Chief Scientific Officer at Novartis Egypt, said that ‘A bedtime story’ campaign seeks to highlight the emotional and psychological burdens borne by ASCVD patients. It also aims to raise the awareness of the importance of reaching the LDL-C target of 55.

According to the World Health Organization (WHO), 46% of all deaths in Egypt are caused by CVD.

“Atherosclerotic cardiovascular diseases (ACVD) place a major burden on our healthcare system,” said Mohamed Ossama, Head of the National Heart Institute, “The long-term impact of these diseases can be damaging to patients, families, and the wider society, and often lead to premature mortality.”

He added that about 37% of Egyptians have elevated LDL-C levels, which often goes unnoticed and untreated.


Categories : healthcare

Finance & Economy

PMC Biogenix Announces Price Increase on Armoslip® and Kemamide® Fatty Amides

2021-05-15 03:00:00

PMC Biogenix Inc. announces that effective June 1, 2021 or as contracts permit, prices for Armoslip and Kemamide brand primary"...
Read More

Schlumberger Appoints Dr. Katharina Beum...
May 15, 2021
Berkshire Hathaway Specialty Insurance E...
May 15, 2021